{
    "id": "0a07ca84-9ad7-4c60-be47-de10955b4098",
    "indications": "lyrica indicated : •management neuropathic pain associated diabetic peripheral neuropathy •management postherpetic neuralgia •adjunctive therapy treatment partial‑onset seizures patients 1 month age older •management fibromyalgia •management neuropathic pain associated spinal cord injury",
    "contraindications": "• adult , begin dosing 150 mg/day . partial‑onset seizure dosing pediatric patients 1 month age older , refer section 2.4 . ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) • dosing recommendations : indication dosing regimen maximum dose dpn pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week . phn ( 2.3 ) 2 3 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . adjunctive therapy partial‑onset seizures pediatric adult patients weighing 30 kg ( 2.4 ) 2 3 divided doses per day maximum dose 600 mg/day . adjunctive therapy partial‑onset seizures pediatric patients weighing less 30 kg ( 2.4 ) 1 month less 4 years : 3 divided doses per day 4 years older : 2 3 divided doses per day 14 mg/kg/day . fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 450 mg/day . neuropathic pain associated spinal cord injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week . maximum dose 600 mg/day . • dose adjusted adult patients reduced renal function . ( 2.7 )",
    "warningsAndPrecautions": "25 mg capsules : white , hard-gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 25 ” body ; available : bottles 90 : ndc 58151-236-77 50 mg capsules : white , hard-gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 50 ” ink band body , available : bottles 90 : ndc 58151-237-77 unit-dose blister packages 100 : ndc 58151-237-88 75 mg capsules : white/orange hard gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 75 ” body ; available : bottles 90 : ndc 58151-238-77 unit-dose blister packages 100 : ndc 58151-238-88 100 mg capsules : orange , hard-gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 100 ” body , available : bottles 90 : ndc 58151-239-77 unit-dose blister packages 100 : ndc 58151-239-88 150 mg capsules : white hard gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 150 ” body , available : bottles 90 : ndc 58151-240-77 unit-dose blister packages 100 : ndc 58151-240-88 200 mg capsules : light orange hard gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 200 ” body , available : bottles 90 : ndc 58151-241-77 225 mg capsules : white/light orange hard gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 225 ” body ; available : bottles 90 : ndc 58151-243-77 300 mg capsules : white/orange hard gelatin capsule printed black ink “ vtrs ” cap , “ pgn ” “ 300 ” body , available : bottles 90 : ndc 58151-242-77 20 mg/ml oral solution : 16 fluid ounce white high density polyethylene ( hdpe ) bottle polyethylene-lined closure : 16 fluid ounce bottle ndc 58151-244-35 storage handling store 25°c ( 77°f ) ; excursions permitted 15°c 30°c ( 59°f 86°f ) ( usp controlled room temperature ) .",
    "adverseReactions": "lyrica contraindicated patients known hypersensitivity pregabalin components . angioedema hypersensitivity occurred patients receiving pregabalin therapy [ ( 5.2 ) ] .",
    "ingredients": [
        {
            "name": "PREGABALIN",
            "code": "55JG375S6M"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "SODIUM LAURYL SULFATE",
            "code": "368GB5141J"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, ANHYDROUS",
            "code": "22ADO53M6F"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        }
    ],
    "organization": "Viatris Specialty LLC",
    "name": "Lyrica",
    "effectiveTime": "20250415",
    "indications_original": "LYRICA is indicated for:\n                  \n                     \n                        •Management of neuropathic pain associated with diabetic peripheral neuropathy\n                     \n                        •Management of postherpetic neuralgia\n                     \n                        •Adjunctive therapy for the treatment of partial‑onset seizures in patients 1 month of age and older \n                     \n                        •Management of fibromyalgia\n                     \n                        •Management of neuropathic pain associated with spinal cord injury",
    "contraindications_original": "• For adult indications, begin dosing at 150 mg/day. For partial‑onset seizure dosing in pediatric patients 1 month of age and older, refer to section 2.4. ( 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) • Dosing recommendations: INDICATION Dosing Regimen Maximum Dose DPN Pain ( 2.2 ) 3 divided doses per day 300 mg/day within 1 week. PHN ( 2.3 ) 2 or 3 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. Adjunctive Therapy for Partial‑Onset Seizures in Pediatric and Adult Patients Weighing 30 kg or More ( 2.4 ) 2 or 3 divided doses per day Maximum dose of 600 mg/day. Adjunctive Therapy for Partial‑Onset Seizures in Pediatric Patients Weighing Less than 30 kg ( 2.4 ) 1 month to less than 4 years: 3 divided doses per day 4 years and older: 2 or 3 divided doses per day 14 mg/kg/day. Fibromyalgia ( 2.5 ) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 450 mg/day. Neuropathic Pain Associated with Spinal Cord Injury ( 2.6 ) 2 divided doses per day 300 mg/day within 1 week. Maximum dose of 600 mg/day. • Dose should be adjusted in adult patients with reduced renal function. ( 2.7 )",
    "warningsAndPrecautions_original": "25 mg capsules:\n                  \n                  White, hard-gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “25” on the body; available in:\n                  Bottles of 90:           NDC 58151-236-77\n                  \n                     50 mg capsules:\n                  \n                  White, hard-gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “50” and an ink band on the body, available in:\n                  Bottles of 90:            NDC 58151-237-77\n                  Unit-Dose Blister Packages of 100:            NDC 58151-237-88\n                  \n                     75 mg capsules:\n                  \n                  White/orange hard gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “75” on the body; available in:\n                  Bottles of 90:            NDC 58151-238-77\n                  Unit-Dose Blister Packages of 100:            NDC 58151-238-88\n                  \n                     100 mg capsules:\n                  \n                  Orange, hard-gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “100” on the body, available in:\n                  Bottles of 90:            NDC 58151-239-77\n                  Unit-Dose Blister Packages of 100:            NDC 58151-239-88\n                  \n                     150 mg capsules:\n                  \n                  White hard gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “150” on the body, available in:\n                  Bottles of 90:            NDC 58151-240-77\n                  Unit-Dose Blister Packages of 100:            NDC 58151-240-88\n                  \n                     200 mg capsules:\n                  \n                  Light orange hard gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “200” on the body, available in:\n                  Bottles of 90:            NDC 58151-241-77\n                  \n                     225 mg capsules:\n                  \n                  White/light orange hard gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “225” on the body; available in:\n                  Bottles of 90:            NDC 58151-243-77\n                  \n                     300 mg capsules:\n                  \n                  White/orange hard gelatin capsule printed with black ink “VTRS” on the cap, “PGN” over “300” on the body, available in:\n                  Bottles of 90:            NDC 58151-242-77\n                  \n                     20 mg/mL oral solution:\n                  \n                  16 fluid ounce white high density polyethylene (HDPE) bottle with a polyethylene-lined closure: \n                  16 fluid ounce bottle           NDC 58151-244-35\n                  Storage and Handling\n                  Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (see USP Controlled Room Temperature).",
    "adverseReactions_original": "LYRICA is contraindicated in patients with known hypersensitivity to pregabalin or any of its components. Angioedema and hypersensitivity reactions have occurred in patients receiving pregabalin therapy [see Warnings and Precautions (5.2)]."
}